Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 1000 iu/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - heparin is indicated for the prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism and occlusive vascular disease. it is also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. heparin is also used as an anticoagulant in blood transfusions

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - heparin sodium 2 iu/ml - solution for infusion - 2 u/ml - active: heparin sodium 2 iu/ml excipient: citric acid monohydrate dibasic sodium phosphate dodecahydrate sodium chloride water for injection - heparin sodium intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - heparin sodium 1000 iu/ml;   - solution for injection - 5000 iu/5ml - active: heparin sodium 1000 iu/ml   excipient: hydrochloric acid sodium hydroxide water for injection

United States - English - NLM (National Library of Medicine)

general injectables & vaccines, inc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin sodium 10000 [usp'u] in 5 ml - heparin sodium is indicated for: atrial fibrillation with embolization: diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and heart surgery; anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (in a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see dosage and administration); prophylaxis and treatment of pulmonary embolism; prophylaxis and treatment of peripheral arterial embolism. heparin sodium should not be used in patients: with severe thrombocytopenia; in whom suitable blood coagulation tests — e.g., the whole blood clotting time, partial thromboplastin time, etc. — cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no ne

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 1000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 26 november 2001: prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. as a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. as an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - heparin sodium - solution for injection concentrate for solution for infusion - heparin sodium 1000 iu/ml - antithrombotic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - heparin sodium 1000 iu/ml; heparin sodium 1000 iu/ml - solution for injection - 1000 iu/ml - active: heparin sodium 1000 iu/ml excipient: hydrochloric acid sodium hydroxide water for injection active: heparin sodium 1000 iu/ml excipient: benzyl alcohol hydrochloric acid sodium hydroxide water for injection

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - heparin sodium - injection - 1000 iu/ml - heparin sodium 1000 iu/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 1000 iu/l - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

United States - English - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 1000 [usp'u] in 1 ml - heparin sodium injection, usp is indicated for: anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see dosage and administration ); prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism. heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures. heparin sodium should not be used in patients with the following conditions: severe thrombocytopenia; when suitable blood coagulation tests, e.g., the whole